Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026
Rhea-AI Summary
Rapid Micro Biosystems (Nasdaq: RPID) will release first quarter 2026 financial results after market close on Wednesday, May 13, 2026. Management will host a live webcast conference call at 4:30 p.m. ET the same day. The live audio webcast is available on the company website and will be archived for replay.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – RPID
On the day this news was published, RPID gained 1.19%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed performance, with momentum data only flagging SERA up about 1.66% on earnings news, suggesting this scheduling update is stock-specific rather than part of a broad sector move.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Earnings date notice | Neutral | +6.3% | Announcement of schedule for Q4 and full-year 2025 earnings release and call. |
Limited history shows the prior earnings date announcement coincided with a modestly positive price reaction.
Over recent months, Rapid Micro Biosystems has reported record 2025 revenue with continued losses, issued 2026 guidance, and highlighted multi-system orders from Amgen and Samsung Biologics. It also participated in multiple healthcare conferences and pre-announced its prior earnings date, which was followed by a 6.3% gain. Today’s first quarter 2026 earnings date notice fits this pattern of regular investor communications ahead of detailed financial releases.
Historical Comparison
In the past year, RPID had one prior earnings-date announcement, which coincided with a 6.3% gain, suggesting such scheduling updates have previously drawn a modestly positive response.
The company continues its practice of pre-announcing earnings dates with webcast details, maintaining consistent investor-relations communication around quarterly reports.
Market Pulse Summary
This announcement sets the timetable for first quarter 2026 results and the related webcast, continuing the company’s pattern of pre-announcing earnings dates. In the recent past, RPID reported record 2025 revenue of $33.6M alongside a $47.1M net loss and an accumulated deficit of $522.4M. Investors may focus on how upcoming results track against 2026 revenue and margin expectations and on any updates to commercialization or capital plans.
Key Terms
webcast technical
AI-generated analysis. Not financial advice.
LEXINGTON, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2026 financial results after the market close on Wednesday, May 13, 2026.
In conjunction with the release, the Company’s management team will host a webcast conference call at 4:30 p.m. ET on Wednesday, May 13, 2026. The live audio webcast will be accessible on the Company’s website and can be accessed with this link. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com Media Contact: media@rapidmicrobio.com